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Abstract
Background: The magnitude of safety risks related to medications of the older adults has been evidenced by
numerous studies, but less is known of how to manage and prevent these risks in different health care settings.
The aim of this study was to coordinate resources for prospective medication risk management of home care
clients ≥ 65 years in primary care and to develop a study design for demonstrating effectiveness of the procedure.
Methods: Health care units involved in the study are from primary care in Lohja, Southern Finland: home care (191
consented clients), the public healthcare center, and a private community pharmacy. System based risk management
theory and action research method was applied to construct the collaborative procedure utilizing each profession’s
existing resources in medication risk management of older home care clients. An inventory of clinical measures in
usual clinical practice and systematic review of rigorous study designs was utilized in effectiveness study design.
Discussion: The new coordinated medication management model (CoMM) has the following 5 stages: 1) practical
nurses are trained to identify clinically significant drug-related problems (DRPs) during home visits and report those to
the clinical pharmacist. Clinical pharmacist prepares the cases for 2) an interprofessional triage meeting (50–70 cases/
meeting of 2 h) where decisions are made on further action, e.g., more detailed medication reviews, 3) community
pharmacists conduct necessary medication reviews and each patients’ physician makes final decisions on medication
changes needed. The final stages concern 4) implementation and 5) follow-up of medication changes. Randomized
controlled trial (RCT) was developed to demonstrate the effectiveness of the procedure.
The developed procedure is feasible for screening and reviewing medications of a high number of older home care
clients to identify clients with severe DRPs and provide interventions to solve them utilizing existing primary care
resources.
Trial registration: The study is registered in the Clinical Trials.gov (NCT02545257). Registration date September 9 2015.
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Background
The magnitude of safety risks related to medications of
the older adults has been evidenced by numerous studies
[1, 2], but less is known of how to manage and prevent
these risks in different health care settings. Since the
1990s, both explicit and implicit criteria have been
established to decrease prescribing of potentially in-
appropriate medicines (PIMs) for the older adults [3–5].
These criteria are useless unless they are implemented
routinely throughout health care. Recently, the imple-
mentation has been facilitated through electronic data-
bases, software applications and clinical decision support
systems (CDSS), which have dramatically evolved over
the last decade [6, 7]. The databases and CDSS systems
can prospectively detect PIMs and other medication
safety risks, but qualified healthcare professionals are
needed to make the final decision using clinical judge-
ment based on comprehensive patient information.
Efficient use of these modern tools and skill-sets
requires coordinated medication management processes
in different healthcare settings.
Finland is one of the countries with advanced national
health portals, databases and prospective screening sys-
tems for managing drug-related risks (Fig. 1) [8–11].
Within less than 20 years, a wide range of medication risk
management tools have been developed, with the Finnish
Medical Society Duodecim playing a major role in their
development [9]. These tools are widely available in
Finnish health care, including community pharmacies.
Even though these innovative prospective medication
risk management tools and databases are widely available
in Finland, they do not form an integrated medication
management process. Health care providers and units
work independently, without coordination, and no one
seems to have clear responsibility for identifying and solv-
ing individual patients’ drug-related problems (DRPs) [12].
The aim of this study was to integrate risk assessment
tools, procedures and databases available in Finland to
Fig. 1 Medication risk management tools and databases launched in Finland since 2004 and currently widely available in health care and
community pharmacies
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form a coordinated medication management model
(CoMM) involving home care nurses and practical
nurses (PNs), physicians and community pharmacists in
the medication process of older home care clients. A
study design was also developed for assessing the effect-
iveness of CoMM.
Methods/Design
Context of the study and its importance for ongoing
social and health services reform in Finland
Health care services in Finland are primarily funded and
organized by municipalities [13]. The services are divided
into primary care and specialized care services. The muni-
cipalities and individual residents may acquire services
from the public and private health care providers or the
third sector. Medicine supply and related pharmaceutical
services for outpatients are provided by private commu-
nity pharmacies. Currently, the Finnish health care system
is undergoing a massive reform [14]. The goal is to im-
prove integration between primary and specialized care
and integrate social and health services from the clients’
perspective. Integration concerns service provision and
funding as they both are currently fragmented.
Long-term home care services for the older adults are
a critically important part of health care delivery in
Finland as in many other countries [15, 16]. Currently
they are mostly based on regular, even daily, encounters
with home care PNs, coordinated by home care nurses.
The allocation of physicians’ time for clients is limited
and will become even more limited in the future as the
proportion of the older adults is increasing [17]. This is
putting more pressure on developing new collaborative
procedures for monitoring benefits and risks of medica-
tion therapies. As part of reorganizing the care PNsʼ
involvement in monitoring medication risks and benefits
could be enhanced, but PNs have the very basics of rele-
vant pharmacotherapy [18]. A need for enhancing phar-
macists’ involvement in medication management of the
older adults is identified [12, 19].
The aim of this study was to coordinate resources for
prospective medication risk management of home care
clients ≥ 65 years in primary care and to develop a study
design for demonstrating effectiveness of the procedure.
Study setting: participating organizations, health
professionals and home care clients
This study is conducted within publicly funded primary
care in Lohja, a municipality in Southern Finland with
47,000 inhabitants. Health care units involved in the study
are: Lohja Home Care Unit, Lohja Health Center, and a
private community pharmacy (Lohja 1st Pharmacy). A
clinically trained researcher (TT) from the research group
coordinated the development of CoMM and the design
for the effectiveness study in close cooperation with the
health care providers involved in home care in Lohja.
Lohja Home Care Unit is divided into five service areas,
each having a leading nurse, nurses and PNs who mostly
conduct home visits. Nurses consult physicians (working
in the Lohja Health Center) as needed, but the physicians
meet the patients infrequently. Community pharmacists
from the Lohja 1st Pharmacy had primarily a standard
BSc(Pharm) or MSc(Pharm) degree with long-term
in-house training for geriatric pharmacotherapy and man-
aging DRPs in the older adults, but a pharmacist with
accreditation in comprehensive medication reviews
(CMRs) [20] was available as needed. All these pharma-
cists are termed “pharmacists” in this report.
Participants
Home care clients were recruited in the study by nurses
and PNs. They individually approached their clients and/
or their closest proxy and invited them to participate in
the study. Announcements in the local newspaper were
also used. The recruitment process was carried out be-
tween September 2015 and December 2015. The inclu-
sion criteria were: 1) ≥ 65 years old, home-dwelling
resident; 2) receives regular home care from the city of
Lohja; 3) uses at least one medicine; 4) voluntary partici-
pation, written informed consent to participate in the
study given by participant or closest proxy.
Study design
This study applied action research method to develop
the CoMM. Action research method is increasingly be-
ing used in health services research [21, 22]. When ap-
plying this method, the researcher works explicitly with
and for people rather than undertaking research on
them [22]. The model development was theoretically
guided by Reason’s systems-based risk management the-
ory on preventing human errors [23], complemented by
Hepler and Strand’s basic principles of identifying, solv-
ing and preventing DRPs [24]. Clyne’s model was applied
for categorization of comprehensiveness of medication
reviews [25].
Development process of CoMM (intervention) and study
design for demonstrating its effectiveness
The goal was to construct a collaborative procedure
which utilizes each profession’s resources in a rational
way. The coordination of the use of the risk manage-
ment tools and resources illustrated in Fig. 1 was part of
the process.
The development process encompassed four main steps
(Fig. 2). During each step, the coordinating pharmacist/re-
searcher (TT) worked closely with the home care nurses
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and PNs, their manager (nurse), physicians involved in
home care and the community pharmacists.
Exploration step (I) included orientation to each or-
ganization’s current medication management practices
targeted to older home care clients. It also covered
identification of medication management tools and
procedures applied locally in Lohja compared to those
generally available in Finland (Fig. 1). Actual tasks
and responsibilities for each professional were defined
in regular joint meetings with the coordinating
pharmacist (TT), the pharmacy owner (ES) and the
responsible nurse of home care service area (KP).
An inventory of clinical measures, used in routine
clinical practice in Lohja Home Care, was conducted to
include them as outcome measures in the effectiveness
study design protocol. The ECHO model, which covers
economic, clinical and humanistic outcomes, was ap-
plied for their selection and categorization [26]. System-
atic review of Kiiski et al. (2016) [27], and other previous
literature were applied to learn about experiences of
rigorous study designs for assessing effectiveness of
collaborative medication management models for the
older home care clients.
Installation step (II) was to prepare the participating
organizations for the CoMM. Home care nurses, PNs,
physicians and pharmacists were informed prior to
the study and encouraged continuously to comment
on the model construction. Personnel training ses-
sions needed to support the model construction were
jointly planned with the researchers and home care
management. The coordinating pharmacist organized
trainings for PNs related to the recruitment process,
medication reconciliation [28] and use of clinical
tests. PNs were also trained on the content and use
of the Drug-Related Problem Risk Assessment Tool
(DRP-RAT) [8, 29] and about Lohja Home Care
Unit’s principles in medication management [30].
Finishing the CoMM (III) aimed to decide the way to
solve the identified clinically significant DRPs and allocate
medication reviews according to the severity of the DRPs.
In the consensus meeting home care physicians, home
care managers, leading nurses, community pharmacists,
Fig. 2 Development process of coordinated medication management model (CoMM) using action research method (modified from Lewin 1946
[21], Meyer 2000 [22])
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coordinating pharmacist and the research group discussed
to agree on tasks and to set up criteria for medication re-
views and their comprehensiveness. Steps and procedures
related to patient information transfer, interprofessional
collaboration and adequate follow-ups were discussed.
After finishing the development of CoMM, its full oper-
ation started (IV). The coordinating pharmacist worked
closely with the home care practitioners and community
pharmacists, facilitating integration between stages and
tasks of the health care providers involved. This enabled
reflection of the model’s feasibility.
Study design for assessing effectiveness of CoMM was
developed and selection of outcome measures was made in
collaboration with Lohja Home Care and the research
group utilizing published evidence on assessing effective-
ness of medication review procedures. Selection was made
considering study purposes, reliability, validity, sensitivity
and specificity of measures and feasibility of carrying out
the measurements in clinical practice. Measures already in
use were prioritized to minimize additional work for nurses
and PNs and inconvenience for the patients.
Description of developed CoMM for home care clients
(intervention)
The developed CoMM consists of five main stages in
which clinically significant DRPs can be identified and
solved using collaborative procedures and medication
reviews (Fig. 3, Table 1). PNs were trained to observe
potential medication risks on routine home visits
more systematically than before and to report de-
tected clinically significant DRPs to the coordinating
pharmacist (Fig. 3: Stage I: Risk Assessment). The co-
ordinating pharmacist prepared the cases for the tri-
age meeting (Fig. 3: Stages I and II), in which the
leading home care physician and the coordinating
pharmacist decided on further actions for clients with
clinically significant DRPs (50–70 cases per triage
meeting of two hours). The actions included more
comprehensive medication reviews according to the
needs of the clients involving their own physicians
and nurses/PNs. In most complicated cases also home
visit and the client’s clinical interview were conducted
(Fig. 3: Stage III). Based on the information gathered
in Stages I-III client’s personal physician made deci-
sions on required actions (Fig. 3: Stage IV) and
follow-up was organized (Fig. 3: Stage V).
Collaborative tasks of each healthcare professional
in the developed model (Fig. 3) are described in
Table 1. Nurses and PNs had a key role in clinical
follow-up and identifying clients with clinically signifi-
cant DRPs through gathering and bringing informa-
tion about clients’ symptoms and signs by DRP-RAT.
Fig. 3 Developed coordinated medication management model (CoMM) for older home care clients
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Community pharmacists’ pharmacotherapeutic skills
were utilized in medication reviews at Stage III
(Fig. 3). Physicians’ resources were allocated for clin-
ical decision making at the triage stage (Stage II) and
for deciding on actions for clients with complicated
DRPs analyzed more in detail in prescription review
(PR), medication review (MR) or comprehensive
medication review (CMR). (Stage IV). The coordinat-
ing pharmacist had a key role in organizing and co-
ordinating medication management processes between
the fragmented organizations involving different
health care providers, and in preparing and participat-
ing in the triage meetings followed by different level
medication reviews.
Description of study design for assessment of CoMM’s
outcomes and effectiveness
Randomized controlled trial (RCT) was selected for
assessing the effectiveness of CoMM.
Table 1 Agreed tasks of each healthcare professional and tools used in the coordinated medication management model (CoMM)
Healthcare professionals Tasks in the coordinated medication
management model
Tools used
Home care nurses
(practical nurses, nurses)
Medication reconciliation
Medication risk assessments
Clinical tests to assess clients’
functioning and disability
(at baseline, 12 and 24 month follow-up)
Medication lists, usual home visits
Clinical interviews with the DRP-RAT
a) Measures used in usual clinical practice:
functional ability (RAVA) [37], physical performance
(The five-times-sit-to-stand test) [38, 39], cognitive
functioning (MMSE) [40], depression (GDS-15) [41]
and malnutrition (MNA) [42].
b) Added measures: difficulties related to urination
(UDI-6) [43], orthostatic hypotension (3 min test) [44]
and alcohol use (AUDIT-C) [45].
Implementing medication changes
and monitoring their outcomes
Regular home visits as usual
Informing physicians when needed
Community pharmacists Prescription review (PR) Clinically significant drug-drug interactions (DDIs)
(SFINX) [32]
Potentially inappropriate medicines (PIMs) according
to Beers 2015 criteria [46], anticholinergic and serotonergic
loads of medicines (Salko) [33].
Medication review (MR) Patient information: medication list, DRP-RAT and glomerulus
filtration rate (GFR) results
Other tools used: SFINX (DDIs), Pharao (Cumulative scoring
of the anticholinergicity, bleeding risk, constipation, orthostatic
hypotension, prolongation of QT interval, nephrotoxicity,
sedation, convulsion risk and serotonergicity of the patient’s
medication) [47], Salko (PIMs) [33], Renbase (Renal function
and appropriateness of doses/medicines used) [9].
Comprehensive medication review
(CMR) conducted by a qualified
pharmacist (TT, SL)
Patient information: medication list, DRP-RAT and GFR results,
diagnosis, laboratory test results.
Tools used: As in MR, complemented by client’s clinical
interview [20, 48]
Coordinating pharmacist Trainings of the PNs for the recruitment
process, CoMM and use of DRP-RAT (MD)
Meetings, discussions, personal guidance, DRP-RAT training [29]
Coordinating and organizing processes
for CoMM
Constructing the CoMM structure through observations,
meetings, contacts and negotiations with organizations,
health care professionals, researchers and home care clients
involved, organizing processes and interactive training,
providing training, guidance and feedback, reflecting the
literature and guidelines on geriatric care and pharmacotherapy
Preparing triage meetings with the leading
home care physician to decide on actions
for clients with clinically significant DRPs
Prescription review findings (from SFINX and Salko databases)
and DRP-RAT results.
Leading home care physician Triage meetings with the coordinating
pharmacist to decide on actions for clients
with clinically significant DRPs
(50–70 cases per triage meeting of 2 h)
Prescription review findings (from SFINX and Salko databases)
and DRP-RAT results.
Client’s personal physician Case-conferences with pharmacists concerning
clients with clinically significant DRPs
identified in MR and CMR.
Decisions on the medication changes and how
they will be implemented.
Medication lists accomplished with the SFINX and Salko data,
DRP-RAT results, results from the clinical tests, laboratory test
(GFR), MR and CMR report, including client’s clinical interview.
Abbreviations: DRP-RAT Drug-Related Problem Risk Assessment Tool [31], MMSE Mini Mental State Examination [40], GDS-15 Geriatric Depression Scale [41], MNA The Mini
Nutritional Assessment [42], UDI-6 Urinary Distress Inventory [43], AUDIT-C Alcohol Use Disorder Identification Test, version C [45], SFINX Drug-drug interaction database’s
new name since March 2017 is INXBASE, Pharao adverse effects database’s new name since March 2017 is RISKBASE
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Trial design
The CoMM study is a randomized controlled superiority
trial with two parallel groups, a 1:1 randomization (inter-
vention and control).
Randomization
Participants were randomized to an intervention group
(IG) and a control group (CG) receiving standard home
care. To prevent contamination between IG and CG and
subsequent dilution of the intervention, participants
were randomized by home care areas (2 areas to the IG,
3 areas to the CG) since each home care area has its
own nursing staff. The randomization was performed by
sealed envelopes. The study is considered as open-label.
The IG (n = 104) received the intervention (CoMM)
during the first year, while the CG (n = 87) received
standard care and received the same intervention after
the first year (delayed intervention as control).
Participant timeline
Selected study period was 2 years with measurements at
baseline (in 2015), and at 12 (in 2016) and 24 months
(in the end of year 2017).
Sample size
The study sample was all home care clients, meeting in-
clusion criteria and giving voluntary informed consent,
in the Lohja Home Care Unit due to the practical, ad-
ministrative and financial issues. Sample size calculations
were not performed.
Outcome measures
Selected primary outcome measures assess appropriate-
ness of the medications used, general health status and
functional ability of the older adults, but also target to
specific symptoms that can be potentially caused as ad-
verse effects of medications (Table 1). Majority of se-
lected clinical measures were used in usual clinical
practice in Lohja Home Care. Medication-specific mea-
sures include assessment of clinically significant DRPs
by using DRP-RAT [31] and electronic screening tools
(SFINX, Salko) for identifying PIMs for the older adults,
anticholinergic and serotonergic load and clinically sig-
nificant drug-drug interactions (DDIs) [32, 33]. Medi-
cines will be classified according to the anatomical
therapeutic chemical (ATC) classification system [34].
Use of health services will be measured as visits to phy-
sicians, frequency of visits of home care personnel and
frequency of hospital days and will be used as a second-
ary outcome.
Data collection methods and data management
Home care nurses and practical nurses conduct clinical
tests and DRP-RAT –assessments, compile medication
lists and deliver the data to the research coordinator
(TT). Pharmacists use case report form in medication
reviews and research coordinator receives the data. Data
are entered into a computerized database by the re-
search coordinator. All patients will be given a unique
study number to preserve confidentiality. The collected
data will be verified for accuracy, missing data, and data
consistency with the documents source (medication lists,
clinical test forms).
Statistical methods
Data will be analyzed on an intention to treat principle,
including all randomized participants in the group to
which they were randomly assigned. Also per protocol
analysis to compare participants from intervention
group with clinically significant medication changes con-
ducted due to CMR, MR or PR, with control group will
be performed.
The effectiveness of intervention compared to controls
receiving standard home care will be first analyzed with
unadjusted analysis. If there exists any group differences
in participant characteristics or clinical outcomes at
baseline, these variables will be included in adjusted
analysis.
Descriptive statistics (mean, median or percentages as
appropriate) will be used to summarize the participant
characteristics and clinical outcomes. The comparison in
the participant characteristics and clinical outcomes at
baseline between groups will be done by two-sample
t-test for normally distributed variables and by Man-
n-Whitney U-test for non-normally distributed variables.
Chi-square test will be used for categorical variables.
Continuous outcomes will be analyzed with analysis of
variance or covariance and repeated measures analysis of
variance or covariance. Dichotomous outcomes will be
analyzed by binary logistic regression and ordinal out-
comes by cumulative logistic regression using general-
ized estimating equations to account for the correlation
between the repeated measurements. Participants with
baseline measurement and at least one follow-up meas-
urement will be included in longitudinal analysis. Two-
sided statistical tests with a 5% level of significance will
be used.
Data monitoring
The research coordinator ensures the successful comple-
tion of the study, and the collection of data. She also en-
sures the compliance with the study protocol, the
organization of the follow-up of the study participants
and receives information about drop-outs.
Harms – End of protocol
Any harm to the participants will not be expected due
to this study. Participating physicians from their own
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health system decide potential changes to patients’ medi-
cation according to their normal clinical practice. Partic-
ipants can withdraw their consent any time.
Protocol amendments
Important protocol amendment would require new eth-
ical approval. Any important amendments have not been
made during the study.
Confidentiality
The personal information of the participants is kept in a
separate file. The research coordinator ensures the pro-
tection of the confidentiality of the data. Personal infor-
mation is not entered to the study database, study
numbers are used instead.
Dissemination policy
The results of the effectiveness study will be published
in a peer-reviewed journal. Separate manuscripts may be
published on primary and secondary outcomes.
Discussion
This study produced a 5-stage medication management
procedure suitable for screening medications of a high
number of home care clients and identifying clients with
potential clinically significant DRPs. The model coordi-
nates existing resources to prospective medication risk
assessment providing also tools to solve identified DRPs.
Nurses and PNs’ role in conducting DRP risk assess-
ments, medication reconciliation and clinical tests dur-
ing their usual home visits was clarified and reinforced.
They also had a key role in implementing and following
up medication changes. Triage meetings was a new and
feasible way for allocating medication reviews according
to clinical needs, but using a minimum of physician’s
time. The coordinating pharmacist prepared triage meet-
ings by summing up each client’s DRP risk information
from different sources and making preliminary proposals
for required actions for physician’s consideration. Com-
munity pharmacists’ contribution changed towards more
clinical in the model. They conducted medication re-
views and worked closer than before with nurses, PNs
and physicians. In future, the coordinating role could be
delegated to community pharmacists.
The model contains an adequate follow-up stage to
confirm that the agreed medication changes will be actu-
ally implemented and the client’s health status moni-
tored. This stage is often missing or omitted, but it is
crucial for obtaining any benefits from DRP risk assess-
ments and medication reviews [27].
The model focuses on clinically significant DRPs
which may occur due to patient-related factors (e.g., age-
related physiological alterations, co-morbidities, poor
adherence), pharmacological effects of the medications
(particularly adverse drug reactions (ADRs), high-risk
medications) or the medication process of the client
(e.g., poor medication management, infrequent follow-
ups, various health care providers) [31]. These are the
aspects that PNs were trained to observe during home
visits by using the DRP-RAT tool as a guide in commu-
nication with their client or the proxy. Home visits were
primarily conducted by clients’ own PNs who knew
them. A clinically trained pharmacist conducted home
visits only in cases in which risk assessment conducted
by a PN indicated serious DRPs needing more detailed
investigation. These cases were a minority in our data.
The CoMM development process revealed educational
needs both in geriatric pharmacotherapy and under-
standing system-based medication risk management.
These needs were identified in all participating health
care professionals and community pharmacists. This
kind of model development processes should include in-
terprofessional training that support competence and
practice development [35]. In our process, home care
nursing staff and physicians had training on identifying
clinically significant DRPs by using DRP-RAT and
deprescribing [8, 31, 36]. Community pharmacists were
identified to need training for conducting DRP risk
assessments and taking more responsibility of the triage
stage in the future. The coordinating pharmacist was a
valuable resource in identifying educational needs and
educating staff.
Our experience is that health care teams in home care
benefit from having a coordinating pharmacist with quali-
fications in CMRs, geriatric pharmacotherapy and system-
based medication risk management. Our study revealed
that organizations and health care units involved in home
care clients’ medication therapy are working independ-
ently in silos, nobody takes holistic responsibility for
medications. The coordinating pharmacist was needed to
facilitate construction of new processes and introduce
new tools and approaches in medication management.
She scheduled the progression of risk management stages
(see Fig. 3) and regularly highlighted the primary goal of
the project to those involved: the purpose being to find a
feasible way to manage and prevent clinically significant
DRPs of the home care clients, not to conduct scientific
research. Practitioners involved were not used to working
in such close collaboration, which was crucial for the
model. Scarce availability of physicians’ resources and
partly reluctant attitudes towards the new collaborative
way of working complicated the arrangement of case-
conferences of MRs and CMRs.
System based risk management perspectives through
Reason’s Swiss Cheese Model [23] and Hepler and
Strand’s model [24], to identify and prevent DRPs, were
useful in guiding model development and constructing a
shared understanding of medication safety and
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prospective medication risk management. Our study in-
dicated that practitioners in Finnish health care are not
well acquainted with systems thinking and this needs
reinforcement in the future.
The strength in using an action research method [21]
in model development lies in its ability to consider prac-
tical challenges and produce solutions, considering exist-
ing resources. The method contributed to the step by
step construction of the CoMM model and description
of the responsibilities of each professional involved in
the model, which is missing in many other studies [27].
Transferring the model to other home care localities is
possible, but will require long term effort from a quali-
fied coordinator, committed personnel and managers to
reach the mature stage of the collaboration that is neces-
sary for sustainable changes in working patterns.
This study produced a RCT with a combination of
outcome measures to assess general health status and
functional ability of the older adults, but also targeted to
symptoms suggestive of adverse effects of medications.
DRP-RAT is used as an outcome measure to evaluate
potential decreases in clinically significant DRPs. Medi-
cation lists are used to investigate changes in the quality
of medications (e.g., use of PIMs). According to previous
evidence, a selected study period of 2 years should be
long enough to demonstrate potential changes in study
participants’ health outcomes, use of health services and
sustainability of changes made in their medications.
The developed CoMM procedure is feasible for screen-
ing and reviewing medications of a high number of older
home care clients to identify clients with severe DRPs and
provide interventions to solve them utilizing existing pri-
mary care resources. The coordinating pharmacist was
needed to facilitate the construction of new processes and
introduce new tools and approaches in medication man-
agement of the older home care clients.
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